paclitaxel micelle formulation (NK-105) / NANO MRNA, Nippon Kayaku - LARVOL DELTA

A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients (ESMO 2017) - "The efficacy of 65 mg/m2 of NK105 could not be verified in terms of non-inferiority of PFS relative to PTX in this study. NK105 safety profile was generally similar to that of PTX, but the NK105 PSN profile was better than that of PTX. NK105 efficacy should be re-evaluated in future studies."

Adverse drug reaction • P3 data • Breast Cancer • Gastric Cancer

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer. (PubMed, Int J Nanomedicine) - "Efficacy was similar in both groups. The PSN profile was better in the NK105 group."

Journal • P2 data • Breast Cancer • Hematological Disorders • Neutropenia • Oncology • Pain • Solid Tumor

KY1055, a novel ICOS-PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. (AACR 2018) - "Finally, we demonstrate that KY1055 depletes TRegs and improves the TEff : TReg ratio in vivo in a CT26 model of tumour growth. Altogether, these data warrant further development of KY1055 for the treatment of solid tumours."

IO Biomarker • PD(L)-1 Biomarker • Preclinical • Solid Tumor

Cancer Nanomedicines Based on Synthetic Polypeptides. (PubMed, Biomacromolecules) - "A few polypeptide-based nanoformulations (e.g., NK105, NC6004, NK911, CT2103) are under phases I-III clinical investigation for treating patients with advanced solid tumors. Moreover, virus-mimicking vehicles have been devised from polypeptides for efficient non-viral delivery of highly potent peptides, proteins, and nucleic acids, greatly advancing biotherapy for cancers. In this perspective, we highlight the state-of-the-art design and fabrication of cancer nanomedicines based on synthetic polypeptides, and at the end give our viewpoints on their future development for targeted cancer therapy and potential challenges for clinical translation."

Journal • Oncology • Psychiatry • Solid Tumor

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. (PubMed, Br J Cancer) - P3; "The primary endpoint was not met, but NK105 had a better PSN toxicity profile than PTX."

Clinical • Head-to-Head • Journal • P3 data

Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line. (PubMed, Pancreas) - "TCC-Pan2 cell line and Pan2MmLuc PD model can serve as useful tools for monitoring the responses to antineoplastic agents and for studying PDAC biology."

Journal • Preclinical